Navigating the Supply Chain for IVIG and Other High-Touch Therapies

Why Supply Chain Matters for High-Touch Therapies

Intravenous Immunoglobulin (IVIG) and similar therapies literally save lives, especially for patients with immunodeficiencies and autoimmune conditions. But the supply chain behind these critical treatments is often fragile. Manufacturing is complex, plasma sourcing is difficult, and the demand is rising. At The Remedy Group, we track these shifts closely to ensure we stay informed about market trends, supply challenges, and the strategies companies are using to keep therapies accessible. By understanding this, we can better support our partners in hiring the right leaders to navigate these pressures and build resilient teams.

Market Growth: Demand Is Rising Fast

• In 2023, the global IVIG market was valued at approximately 12.7 billion dollars, and forecasts show it could grow to 23.5 billion by 2034. [BioSpace]
• Other estimates place the broader immunoglobulin market at 18.9 billion in 2024, expected to nearly double to 36.7 billion by 2034. [Biotech Beyond Borders]
• In North America, IVIG alone accounted for more than 42% of the global market share in 2024. [Mordor Intelligence]

⠀Bottom line: Demand isn’t just steady, it’s accelerating. Driven by rising diagnoses and expanding therapy indications.

Ongoing Supply Pressures: Persistent Shortages, Few Solutions

• A 2024 international survey found over 60% of respondents reported shortages of immunoglobulin products, yet fewer had well-developed solutions in place. [Erasmus University Rotterdam]

• Similarly, a 2024 BEST Collaborative survey of hospitals in the USA, Canada, Europe, Japan, and Australia confirmed that more than 60% experienced IVIG supply shortages, but again, well-structured mitigation plans were often missing. [Erasmus University Rotterdam]

Key Supply Chain Challenges

• Plasma sourcing constraints: Plasma collection remains time-consuming, governed by strict donor criteria and regulatory requirements. Growing demand outpaces expansion of collection capacity. [PMC]
• Manufacturing complexity: IVIG production involves multiple purification and virus-inactivation steps. Scaling this safely and quickly remains challenging.
• Geopolitical & regulatory risks: Policies, import/export barriers, and global events (pandemics, conflicts) can disrupt raw material flow and production. [arXiv – Cornell University]
• Consolidation risk: Production interruptions such facility shutdowns and quaity control issues can trigger far-reaching consequences.

⠀Bright Spots in Innovation & Resilience

• Advances in manufacturing, like continuous chromatography and improved purification are boosting yields and consistency while reducing bottlenecks. [BioSpace]
• Diversification of products: The launch of new IVIG brands and strength formulations (e.g., ALYGLO 10%) is helping expand supply options and capacity globally. [PR Newswire]
• Growing home IVIG utilization: Medicare data show home-based IVIG visits rose from 4,845 in Q1 2022 to 5,745 by Q4 2023, showing a 2.6% quarterly rise on average. After policy changes in 2024, home IVIG visits jumped 18.7% from Q4 2023 to Q1 2024, and 12.4% from Q1 to Q2 2024. The number of approved suppliers also rose 44%, from 90 to 130. [Centers for Medicare & Medicaid Services]

This shift highlights opportunities to ease pressure on facility infusions while improving patient access.

5 Ways to Build a Stronger Supply Chain

1. Have backups ready
Relying on just one supplier is risky. Keeping extra inventory and having backup sources ensures patients aren’t left waiting when delays happen.

2. Expand plasma collection
Gathering plasma from more regions spreads out the risk and keeps supply more consistent.

3. Work together, not against each other
When manufacturers, providers, and clinicians share information and align on priorities, it prevents hoarding and makes sure the right patients get treated first.

4. Offer different care options
Home infusion or SCIg (subcutaneous immunoglobulin) can take pressure off crowded infusion centers while giving patients more flexibility.

5. Stay close to regulators
Engaging early with policymakers helps spot roadblocks sooner and speed up approvals when they matter most.

Conclusion
IVIG and similar high-touch therapies are only as reliable as the supply chain that delivers them. With growing demand, vulnerability to disruptions, and evolving patient needs, we must lean into innovation, strategic partnerships, and flexible delivery models.

At The Remedy Group, our mission is connecting clinical excellence with supply chain insight because every patient relying on these therapies deserves care without interruption.